journal
MENU ▼
Read by QxMD icon Read
search

Allergy and Asthma Proceedings:

journal
https://www.readbyqxmd.com/read/30157993/human-factors-engineering-validation-study-for-a-novel-0-1-mg-epinephrine-auto-injector
#1
Evan Edwards, Catherine Kessler, Naomi Cherne, Emily Dissinger, Adam Shames
BACKGROUND: Anaphylaxis in infants and young children is increasing. Historically, epinephrine auto-injectors (EAI) werenot available in a dose or platform designed for patients who weighed less than 15 kg, and, therefore, 0.15-mg EAIs were prescribed for these patients. Results of ultrasound studies indicate that currently marketed 0.15-mg EAIs have needle lengths that may strike bone in ~29 to 43% of patients who weigh less than 15 kg and result in possible intraosseous injection. An EAI with a more weight-appropriate 0...
August 29, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/29954477/efficacy-of-recombinant-human-c1-esterase-inhibitor-across-anatomic-locations-in-acute-hereditary-angioedema-attacks
#2
James W Baker, Jonathan A Bernstein, Joseph R Harper, Anurag Relan, Marc A Riedl
BACKGROUND: Hereditary angioedema (HAE) may occur at or spread to multiple anatomic locations during an acute attack. Recombinant human C1 esterase inhibitor (rhC1-INH) is approved for treating acute HAE attacks. OBJECTIVE: To examine the time to the beginning of symptom relief with rhC1-INH by attack location. METHODS: Data for patients ≥12 years of age with an acute HAE attack who received rhC1-INH 50 IU/kg or placebo were pooled from two double-blind clinical trials with open-label extensions...
September 28, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/30037361/randomized-dose-ranging-study-of-a-budesonide-metered-dose-inhaler-by-using-co-suspension-delivery-technology-in-asthma
#3
S David Miller, Jack Nyberg, Shahid Siddiqui, Paul Dorinsky, Earl St Rose, Colin Reisner
BACKGROUND: This is the first study of the inhaled corticosteroid, budesonide, delivered by metered-dose inhaler (BD MDI) using innovative co-suspension delivery technology in adults with asthma. OBJECTIVE: To characterize the effects of BD delivered by MDI on lung function and safety. METHODS: Randomized, double-blind, 4-week cross-over, placebo-controlled, phase IIb study of adults (18-65 years of age) with mild-to-moderate persistent asthma...
September 23, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/30107868/subcutaneous-c1-esterase-inhibitor-to-prevent-hereditary-angioedema-attacks-safety-findings-from-the-compact-trial
#4
H Henry Li, Sarah Mycroft, Sandra Christiansen, Daniel N Wood, Henrike Feuersenger, Dipti Pawaskar, Iris Jacobs
BACKGROUND: The first subcutaneous (SC) C1-esterase inhibitor concentrate (C1-INH) was approved by the U.S. Food and Drug Administration in June 2017 as routine prophylaxis to prevent hereditary angioedema attacks in adolescents and adults at a dose of 60 IU/kg twice weekly based on the phase III Clinical Study for Optimal Management of Preventing Angioedema With Low-volume Subcutaneous C1-Inhibitor Replacement Therapy (COMPACT) trial. OBJECTIVE: This article aimed to evaluate the relationship of the C1-INH (SC) dose regimens tested in the COMPACT trial (40 IU/kg and 60 IU/kg twice weekly) and the occurrence of adverse events (AEs)...
September 14, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/30103840/cost-impact-of-monitoring-exhaled-nitric-oxide-in-asthma-management
#5
Renée J G Arnold, Andrew Layton, Marc Massanari
BACKGROUND: Asthma guidelines recommend periodic assessment of impairment and risk factors to prevent exacerbations, which can lead to hospitalization and increased health care utilization and cost. According to recent meta-analysis data, fractional exhaled nitric oxide (FeNO) monitoring is associated with a 40-50% reduction in the risk of exacerbations. OBJECTIVE: Cost modeling of these data indicates the potential for significant cost savings with FeNO use. Therefore, we attempted to verify this potential for cost savings within a real-world data base of Medicare beneficiaries...
September 13, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/30077185/seasonal-variability-of-exacerbations-of-severe-uncontrolled-eosinophilic-asthma-and-clinical-benefits-of-benralizumab
#6
Lawrence DuBuske, Paul Newbold, Yanping Wu, Frank Trudo
BACKGROUND: Benralizumab is a humanized, afucosylated, monoclonal antibody that targets interleukin-5 receptor alpha and induces direct, rapid, and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. In the United States, benralizumab is indicated for add-on maintenance treatment of patients ≥12 years old with severe asthma and an eosinophilic phenotype. OBJECTIVE: This study evaluated the effect of benralizumab treatment on seasonal asthma exacerbation rates for patients with severe, uncontrolled asthma...
September 4, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/30153893/abstracts-from-the-eastern-allergy-conference-may-31-june-3-2018-palm-beach-florida
#7
(no author information available yet)
No abstract text is available yet for this article.
September 1, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/30153892/for-the-patient
#8
(no author information available yet)
No abstract text is available yet for this article.
September 1, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/30153891/a-45-year-old-man-with-elevated-levels-of-immunoglobulin-a
#9
Emily H Liang, Kellie Lim, Shefali A Samant, Javed Sheikh
Quantitative immunoglobulin tests are often ordered as part of the initial evaluation for suspected immune deficiency. Although alterations in immunoglobulin levels can explain recurrent infections, in a patient without symptoms, there are a variety of other factors that can alter immunoglobulin levels. Common causes for elevated immunoglobulin A levels include malignancy and hepatic impairment in addition to a variety of infiltrative, infectious, and inflammatory diseases. We present a case of a 45-year-old man with a history of recurrent sinopulmonary symptoms without bacterial infection found to have an isolated elevated level of immunoglobulin A...
September 1, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/30153890/human-factors-study-of-a-newly-approved-prefilled-syringe-of-epinephrine-for-the-treatment-of-anaphylaxis
#10
Ronald B Moss, Thomas Moll, Karen Daniels, Dennis J Carlo
BACKGROUND: Epinephrine remains the treatment of choice for acute anaphylaxis. However, currently available autoinjectors are costly, and studies have demonstrated human factor issues that result in incorrect use as well as device failures. OBJECTIVE: A recent U.S. Food and Drug Administration approved prefilled syringe of epinephrine for the treatment of anaphylaxis was examined in a prospective human factors validation study to determine the likelihood that the product would be used effectively by intended users...
September 1, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/30153889/camel-s-milk-allergy
#11
Mohammad Ehlayel, Abdulbari Bener
INTRODUCTION: Camel's milk is a safe and therapeutic nutrient. Camel's milk allergy is almost unknown. OBJECTIVE: To identify the clinical and laboratory features of camel's milk allergy. METHODS: In this retrospective study, the records of patients with camel's milk allergy were reviewed. Data collected included age, sex, clinical presentation, concomitant allergies, family history, laboratory tests (complete blood cell count [CBC], white blood cell [WBC] count, total immunoglobulin E [IgE], food specific IgE), and skin-prick tests (SPT) to camel's milk and other foods...
September 1, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/30153888/improved-diagnostic-clarity-in-shrimp-allergic-non-dust-mite-sensitized-patients
#12
Karen Thursday S Tuano, Sara Anvari, Imelda Celine Hanson, Joud Hajjar, Filiz Seeborg, Lenora M Noroski, Danielle Guffey, Grace Kang, Jordan Scott Orange, Carla M Davis
BACKGROUND: Allergen specific immunoglobulin E (sIgE) levels predictive of shrimp allergy have not been identified, but these may be helpful in identifying patients at risk for shrimp-induced allergic reactions. OBJECTIVE: This study sought to identify component resolved diagnostic tests useful for diagnosis of shrimp allergy in patients with or without house-dust mite (HDM) sensitization to the major allergen cysteine protease (Der p 1). METHODS: Patients with positive skin-prick test (SPT) results and/or sIgE values were recruited...
September 1, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/30153887/factors-that-predict-disease-severity-in-atopic-dermatitis-the-role-of-serum-basal-tryptase
#13
Umit Murat Sahiner, Betul Buyuktiryaki, Hatice Eke Gungor, Neriman Sahiner, Abdullah Turasan, Yasemin Altuner Torun, Bulent Enis Sekerel
BACKGROUND: Increased numbers of mast cells that contain tryptase are found in lesional atopic dermatitis (AD) skin. The association of serum basal tryptase (sBT) with anaphylactic reactions and mast cell diseases has recently been shown in children with venom and food allergy. OBJECTIVE: We aimed to identify the risk factors that predict the severity of AD and the association of sBT levels with AD and disease severity. METHOD: AD diagnosis was made according to Hanifin and Rajka criteria...
September 1, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/30153886/meta-analysis-of-randomized-controlled-trials-for-the-efficacy-and-safety-of-anti-interleukin-13-therapy-with-lebrikizumab-in-patients-with-uncontrolled-asthma
#14
Ying Liu, SuZhong Zhang, Ruie Chen, Jieshu Wei, Guanheng Guan, Manru Zhou, Nan Dong, Yingnan Cao
BACKGROUND: Several studies have evaluated the efficacy and safety of lebrikizumab treatment with uncontrolled asthma. However, most of these studies were small and conclusions were inconsistent. Furthermore, whether serum periostin can act as a good predictor of the response to lebrikizumab treatment is still not certain. METHOD: We conducted a systematic review and meta-analysis of randomized controlled trials to evaluate the efficacy and safety of lebrikizumab treatment with uncontrolled asthma...
September 1, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/30153885/hereditary-angioedema-revisited
#15
Joseph A Bellanti, Russell A Settipane
No abstract text is available yet for this article.
September 1, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/29559031/open-label-safety-assessment-of-bilastine-in-elderly-patients-with-allergic-rhinoconjunctivitis-and-or-urticaria
#16
Ander Sologuren, Rosa Viñas, Esther Cordón, Susana E Riesgo, María Del Mar Forés, María Rosa Senán, Sonia Fernández, Luis Labeaga, Manuel Ruiz-Miján
BACKGROUND: Bilastine is an H1-antihistamine approved for symptomatic treatment of patients with allergic rhinoconjunctivitis or urticaria. The safety profile of bilastine in clinical trials of allergic rhinoconjunctivitis or urticaria, assessed by type and frequency of adverse events (AE), was similar to that of placebo. OBJECTIVE: As part of the risk management plan for bilastine, the safety profile of bilastine in the elderly was assessed. METHODS: A prospective, multicenter, observational, open-label, 3-month follow-up study was performed to assess the safety profile of bilastine 20 mg in patients aged ≥65 years with allergic rhinoconjunctivitis and/or urticaria...
July 20, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/30111442/physician-diagnosed-eczema-is-an-independent-risk-factor-for-incident-mouse-skin-test-sensitization-in-adults
#17
Torie Grant, Jennifer Dantzer, Corinne Keet, Roger Peng, Beverly J Paigen, Mary Krevans, Karol Hagberg, Jean Curtin-Brosnan, Wayne Shreffler, Elizabeth C Matsui
BACKGROUND: The disrupted skin barrier in eczema has been associated with an increased risk of immunoglobulin E (IgE) sensitization in childhood. However, it is unclear whether eczema, independent of atopy, is a risk factor for the development of allergic sensitization in adulthood. OBJECTIVE: To determine if skin barrier dysfunction, independent of atopy, is a risk factor for incident sensitization in adult workers at a mouse production and research facility. METHODS: New employees at The Jackson Laboratory enrolled in a cohort study and underwent skin-prick testing (SPT) at baseline and every 6 months to mouse and to a panel of aeroallergens (net wheal ≥3 mm indicated a positive SPT result)...
July 1, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/30095402/erratum
#18
(no author information available yet)
No abstract text is available yet for this article.
July 1, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/30095401/feasibility-of-structured-light-plethysmography-for-the-evaluation-of-lung-function-in-preschool-children-with-asthma
#19
Michele Ghezzi, Laura Tenero, Michele Piazza, Marco Zaffanello, Giulia Paiola, Giorgio L Piacentini
BACKGROUND: Structured light plethysmography (SLP) is a new noninvasive technology to capture the movement of the thoracic and abdominal wall, and to assess some parameters indicative for lung function. OBJECTIVE: The purpose of the study was to evaluate the feasibility of SLP in children with asthma. METHODS: A total of 52 patients were enrolled: 25 with asthma exacerbation (group 1), 13 with well-controlled asthma (group 2), and 14 healthy controls (group 3)...
July 1, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/30095400/differences-in-cytokine-levels-between-the-nasal-polyps-of-adolescents-with-local-allergic-and-adolescents-with-allergic-or-nonallergic-rhinitis
#20
Young-Jin Choi, Ha-Na Kang, Joo-Hwa Kim, Jae-Won Oh, Jin Hyeok Jeong
BACKGROUND: Local allergic rhinitis (LAR) is rhinitis with a localized nasal allergic response in the absence of systemic allergy. This study aimed to evaluate the pathogenesis specific to LAR compared with allergic rhinitis (AR) and nonallergic rhinitis (NAR) by using cytokines from polypous tissues. METHODS: We recruited 43 patients with AR (n = 15; mean age, 17.4 years), LAR (n = 12; mean age, 15.9 years), and NAR (n = 16; mean age, 15.6 years) who underwent polypectomy...
July 1, 2018: Allergy and Asthma Proceedings:
journal
journal
32461
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"